As of June 30, 2026, Arctic Bioscience AS carries a market capitalization of 87.34M, placing it among publicly traded companies globally. Its enterprise value stands at 167.56M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.
| Market Cap | 87.34M |
| Enterprise Value | 167.56M |
As of June 30, 2026, Arctic Bioscience AS has 26.96M shares outstanding.
| Shares Outstanding | 26.96M |
These figures are as of June 30, 2026.
| PB Ratio | 0.56 |
| P/TBV Ratio | -1.53 |
As of June 30, 2026, Arctic Bioscience AS maintains a current ratio of 0.60, meaning it holds 0.6x the short-term assets needed to cover near-term liabilities.
| Current Ratio | 0.60 |
| Debt / Equity | 51.69 |
These figures cover the twelve months ended June 30, 2026.
| Employee Count | 19.00 |
As of the close on November 17, 2026, Arctic Bioscience AS's stock has declined approximately 32.80% over the past 52 weeks. The 50-day moving average sits at 2.58, while the 200-day moving average is 3.09.
| 52-Week Price Change | -32.80% |
| 50-Day Moving Average | 2.58 |
| 200-Day Moving Average | 3.09 |
As of June 30, 2026, Arctic Bioscience AS holds 134,436.00 in cash and equivalents against 80.36M in total debt, resulting in a net debt position of 79.71M. Total book value stands at 155.47M, with working capital of -35.50M providing operational flexibility.
| Cash & Cash Equivalents | 134,436.00 |
| Total Debt | 80.36M |
| Net Debt | 79.71M |
| Equity (Book Value) | 155.47M |
| Book Value Per Share | 5.77 |
| Working Capital | -35.50M |
Already premium?